产品名称

AZD 0530 difumarate - Saracatinib

产品货号

Axon 1456 CAS [893428-72-3] MF C27H32ClN5O5.2C4H4O4MW 774.17 Purity: 99% Soluble in DMSO Description An orally bioavailable tyrosine kinase inhibitor, specifically targeting Src and Abl, those kinases often overexpressed in chronic myeloid leukema cells. Optimal water-soluble form References Certificates Categories Extra info H Laurent et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465. YM Chang et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 1–11. PM Gwanmesia et al. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 2009, 9, 53. TP Green et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology 2009, 3(3), 248-261. C Dulsat et al. Saracatinib. Drugs Fut. 2009, 34(2), 106. Certificate of Analysis Material Safety Data Sheet Cell Signaling & Oncology SRC ABL EC 2.7.10.2 Inhibitor of SRC and ABL tyrosine kinases Chemical name (5-Chloro-benzo[1,3]dioxol-4-yl)-[7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-5-(tetrahydro-pyran-4-yloxy)-quinazolin-4-yl]-amine (2E)-2-butenedioate (1:2) Parent CAS No. [379231-04-6] Order Size Unit Price Stock 5 mg €105.00 In Stock

产品价格

现货询价，电话：010-67529703

产品规格

产品品牌

axonmedchem

产品概述

产品详情

AZD 0530 difumarate - Saracatinib

Based on 8 reference(s) in Google Scholar 9 10 8

Axon 1456

CAS [893428-72-3]

MF C27H32ClN5O5.2C4H4O4
MW 774.17

Purity: 99%
Soluble in DMSO

AZD 0530 difumarate

Description

An orally bioavailable tyrosine kinase inhibitor, specifically targeting Src and Abl, those kinases often overexpressed in chronic myeloid leukema cells. Optimal water-soluble form

H Laurent et al. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-(tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J. Med. Chem. 2006, 49, 6465.

YM Chang et al. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530. Oncogene 2008, 1–11.

PM Gwanmesia et al. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines. BMC Cancer 2009, 9, 53.

TP Green et al. Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530. Molecular Oncology 2009, 3(3), 248-261.

C Dulsat et al. Saracatinib. Drugs Fut. 2009, 34(2), 106.

Inhibitor of SRC and ABL tyrosine kinases

Chemical name

(5-Chloro-benzo[1,3]dioxol-4-yl)-[7-[2-(4-methyl-piperazin-1-yl)-ethoxy]-5-(tetrahydro-pyran-4-yloxy)-quinazolin-4-yl]-amine (2E)-2-butenedioate (1:2)

Parent CAS No.

[379231-04-6]

产品资料